SGSrujan Ganta

Srujan Ganta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Srujan Ganta has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dramatic Remodeling of Hypoplastic Pulmonary Arteries by Pulmonary Valve Opening, Right Ventricular Outflow Stenting, and Aortopulmonary Collateral Lung Territory Incorporation

    by Marjan Hesari, Derek Van, Srujan Ganta, Justin Ryan, Jessica Haley, Jose Silva Sepulveda, Rohit Rao, Brent Gordon, John Nigro, Howaida G. El-Said

  • Open Access

    Single ventricle care: challenges, successes and the future in a single center program

    by Srujan Ganta, Mathew J. Bock, Jessica Haley, Howaida El-Said, Rohit Rao, John J. Nigro

    Congenital cardiac surgery has advanced considerably over the last 4 decades with improvements in virtually every aspect of care. Technical procedures are well described in literature and taught globally while expected results are published in databases such as the Society of Thoracic Surgery (STS) and European Association of Cardio-Thoracic Surgery (EACTS). Outcomes have progressed from uncertain survival to expected program mortalities of nearly 2%. This has been driven in part by advances in surgical technique, but also incremental improvements in the entire patient care pathway. Single ventricles (SVs) remain one of our most challenging cohorts of patients and our most resource intensive. Although outcomes have improved in the past decades, overall morbidity and mortality exceeds that of our biventricular patients. Our goal is to highlight some of the impactful advances surrounding SV care, discuss some of the ideology that led us to our current care processes as it applies to our single center program. We also discuss areas of improvement in the future. We have also focused on mechanical support and transplantation as it remains a keystone in SV care. We hope to provide insight into how to improve the care of patients born with SV disease.

  • Surgical Repair of Double Outlet Right Ventricle Infants Guided by Three Dimensional-Computed Tomography Cardiac Modeling and Printing

    by Srujan Ganta, Justin R. Ryan, Michael J. Lewis, John J. Nigro

    Background: Double outlet right ventricle (DORV) is a challenging congenital cardiac lesion to surgically master. We utilize computed tomography–guided-three-dimensional (3D) modeling/printing and novel in-house software to delineate anatomical relationships providing operative insight into the surgical approach. Our intent is to highlight this and showcase our technology. Methods: We have created a repository of 3D heart reconstructions allowing for review of DORV patients. 3D intraoperative software anatomical manipulation and physical 3D prints were used to gain insight into DORV anatomy with the assistance of an on-site 3D Lab. The software used (Arc 3D Model Viewer) was designed in-house by our 3D Lab, tested and refined through ongoing use by our cardiothoracic surgery team. It allows for the subtraction and addition of anatomical structures and rotation in all axes. Clinicians can pan into the heart and determine specific anatomical boundaries and relationships. Results: From 2010 to 2023, our program operated on 71 patients with DORV and our 3D lab has reconstructed 29 3D-hearts. Reconstructions were analyzed using Arc 3D Model Viewer. 3D reconstructions were viewed in our care conferences and intraoperatively allowing for discussion and determination of the optimal operative approach. Overall survival for DORV patients was 96% (68/71) with two mortalities in patients who did not receive 3D reconstructions. Conclusion: 3D reconstruction has allowed decision-making to be moved out of the operating room into the preoperative planning phase. 3D reconstruction is now standard for all DORV patients in our surgical service. We hope to demonstrate this technology with our newly developed Arc 3D Model Viewer and summarize our clinical results.


  • Myocardial Infarction in a Seven-Year-Old Girl With Left Atrial Myxoma

    by Srujan Ganta, Danielle Strah, Natalie Ellington, Dana Mueller, John J. Nigro, Paul Grossfeld

    Left atrial (LA) myxomas are benign neoplasms that are rare in children. Their presentation is dependent on size and location. We describe a seven-year-old girl who was admitted with chest pain, upper respiratory symptoms, and persistent troponin elevation with suspected myocarditis. Workup revealed an infarction from a LA myxoma which embolized to her right coronary artery–posterior lateral branch (PLB). She underwent prompt successful surgical excision of the myxoma. We elected not to perform a coronary artery embolectomy and her infarction was managed medically. We describe this unique clinical scenario and the decision-making process leading to a successful outcome.

  • Open Access

    Comparing Neurodevelopmental Outcomes in Infants With Patent Ductus Arteriosus Stenting Versus Blalock-Taussig-Thomas Shunt: A Pilot Study

    by Howaida El-Said, Amira Hussein, Katherine Price, Jessica Heibel, Jessica Haley, Shylah Haldeman, Zeinab Boulil, Matthew Brigger, Aparna Rao, Srujan Ganta, et al.


  • Open Access

    Stage 1 and 2 Palliation: Comparing Ductal Stenting and Aorto-Pulmonary Shunts in Single Ventricles with Duct-Dependent Pulmonary Blood Flow

    by Srujan Ganta, Jessica Haley, Howaida El-Said, Brian Lane, Shylah Haldeman, Tara Karamlou, John Moore, Rohit Rao, John J. Nigro

    Patent ductus arteriosus stenting (PDAS) for ductal-dependent pulmonary blood flow (DDPBF) provides a new paradigm for managing neonates with single ventricles (SV). Currently, sparse data exist regarding outcomes for subsequent palliation. We describe our experience with inter-stage care and stage 2 (S2P) conversion with PDAS in comparison to a prior era of patients who received surgical aorto-pulmonary shunts (APS). Retrospective review of 18 consecutive DDPBF SV patients treated with PDAS between 2016 and 2021 was done and compared with 9 who underwent APS from 2010 to 2016. Patient outcomes and pulmonary artery (PA) growth were analyzed. S2P was completed in all 18 with PDAS with no cardiac arrests and one post-S2P mortality. In the 9 APS patients, there was one cardiac arrest requiring ECMO and one mortality inter-stage. Off cardiopulmonary bypass strategy was utilized in 10/18 in the PDAS and 1/9 in the APS group (p = 0.005) at S2P. Shorter ventilation time, earlier PO feeding, and shorter hospital stay were noted in the PDAS group (p = 0.01, p = 0.006, p = 0.03) (S2P). Median Nakata index increase inter-stage was not significant between the PDAS and APS at 94.1 mm2/m2 versus 71.7 mm2/m2 (p = 0.94). Median change in pulmonary artery symmetry (PAS) was − 0.02 and − 0.24, respectively, which was statistically significant (p = 0.008). Neurodevelopmental outcomes were better in the PDAS group compared to the APS group (p = 0.02). PDAS provides excellent PA growth, inter-stage survival, progression along multistage single-ventricle palliation, and potentially improved neurodevelopmental outcomes. Most patients can be transitioned through 2 stages of palliation without CPB.


  • Open Access

    Bronchial Remodeling Following Airway Stenting in Pediatric Patients With Tracheobronchial and Congenital Heart Disease

    by Howaida El-Said, Katherine Price, Amira Hussein, Srujan Ganta, Aparna Rao, John Nigro, Matthew T. Brigger


  • Surgical Mitral Valve Replacement Using a Catheter-Based MelodyTM Valve in a Landing Zone Constructed With a PTFE-Covered Expandable Cheatham-PlatinumTM Stent

    by Howaida El-Said, Amira Hussein, Srujan Ganta, Justin Ryan, John Nigro

    Mitral valve replacement using a Melody valve is a promising solution to the challenge of surgical mitral valve replacement in infants with a hypoplastic annulus. We report the creation of a landing zone in the mitral valve annulus using a Cheatham-Platinum (CP)-covered stent that facilitates Melody valve placement, helps prevent paravalvular leak, minimizes left ventricular outflow tract obstruction, and allows for potential future dilation of the valve.

  • Neonatal Myocardial Infarction: A Proposed Algorithm for Coronary Arterial Thrombus Management

    by Hannah El-Sabrout, Srujan Ganta, Peter Guyon, Kanishka Ratnayaka, Gabrielle Vaughn, James Perry, Amy Kimball, Justin Ryan, Courtney D. Thornburg, Suzanne Tucker, et al.

    Background: Neonatal myocardial infarction is rare and is associated with a high mortality of 40% to 50%. We report our experience with neonatal myocardial infarction, including presentation, management, outcomes, and our current patient management algorithm. Methods: We reviewed all infants admitted with a diagnosis of coronary artery thrombosis, coronary ischemia, or myocardial infarction between January 2015 and May 2021. Results: We identified 21 patients (median age, 1 [interquartile range (IQR), 0.25–9.00] day; weight, 3.2 [IQR, 2.9–3.7] kg). Presentation included respiratory distress (16), shock (3), and murmur (2). Regional wall motion abnormalities by echocardiogram were a key criterion for diagnosis and were present in all 21 with varying degrees of depressed left ventricular function (severe [8], moderate [6], mild [2], and low normal [5]). Ejection fraction ranged from 20% to 54% (median, 43% [IQR, 34%–51%]). Mitral regurgitation was present in 19 (90%), left atrial dilation in 15 (71%), and pulmonary hypertension in 18 (86%). ECG was abnormal in 19 (90%). Median troponin I was 0.18 (IQR, 0.12–0.56) ng/mL. Median BNP (B-type natriuretic peptide) was 2100 (IQR, 924–2325) pg/mL. Seventeen had documented coronary thrombosis by cardiac catheterization. Seventeen (81%) were treated with intracoronary tPA (tissue-type plasminogen activator) followed by systemic heparin, AT (antithrombin), and intravenous nitroglycerin, and 4 (19%) were treated with systemic heparin, AT, and intravenous nitroglycerin alone. Nineteen of 21 recovered. One died (also had infradiaphragmatic total anomalous pulmonary venous return). One patient required a ventricular assist device and later underwent heart transplant; this patient was diagnosed late at 5 weeks of age and did not respond to tPA. Nineteen of 21 (90%) regained normal left ventricular function (ejection fraction, 60%–74%; mean, 65% [IQR, 61%–67%]) at latest follow-up (median, 6.8 [IQR, 3.58–14.72] months). Two of 21 (10%) had residual trivial mitral regurgitation. After analysis of these results, we present our current algorithm, which developed and matured over time, to manage neonatal myocardial infarction. Conclusions: We experienced a lower mortality rate for infants with neonatal infarction than that reported in the literature. We propose a post hoc algorithm that may lead to improvement in patient outcomes following coronary artery thrombus.